Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, PT199, the TWINPEAK study with PT886 and the SKYBRIDGE study with PT217. Both PT886 and PT217 are first-in-class bispecific antibodies and have been granted orphan drug designation as well as Fast Track designation by the FDA. The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer. For more information about Phanes Therapeutics, please visit www.phanesthera.com. For business development or media inquiries, please contact bd@phanestx.com or media@phanestx.com respectively.
Looking for a particular Phanes Therapeutics, Inc. employee's phone or email?
Phanes Therapeutics, Inc. Questions
The Phanes Therapeutics, Inc. annual revenue was $5.1 million in 2026.
Rita Laeufle is the Chief Medical Officer of Phanes Therapeutics, Inc..
24 people are employed at Phanes Therapeutics, Inc..
Phanes Therapeutics, Inc. is based in San Diego, California.
The NAICS codes for Phanes Therapeutics, Inc. are [541, 5417, 54, 54171, 541714].
The SIC codes for Phanes Therapeutics, Inc. are [873, 87].
Top Phanes Therapeutics, Inc. Employees
-
Rita Laeufle
Chief Medical Officer at Phanes Therapeutics, Inc.
San Diego, CA, US31 -
41
-
25+
-
11
-
Chelsea Johnson
Executive Director, Clinical Science and Operations at Phanes Therapeutics, Inc.
San Diego, California, United States11 -
Albert Lam
Director of Process Development at Phanes Therapeutics, Inc.
San Diego, CA, US12 -
Jack Li
Principal Scientist at Phanes Therapeutics, Inc.
California, United States25+
Related Companies
